Arcutis outlines $535M-$545M 2026 net revenue guidance while preparing for February 23, 2027 infant AD PDUFA
Earnings Call Insights: Arcutis Biotherapeutics (ARQT) Q3 2026
Management View
“Net product revenues were $143.9 million,” and this reflected “robust sales performance and demand-driven growth,” according to (President, CEO & Director Todd Watanabe), who also said the company is “reinvesting the cash flow we’re generating from ZORYVE back into the
Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.